TY - JOUR
T1 - Generation of human parallel chimeric antigen receptor (pCAR) T cells to achieve synergistic T cell co-stimulation
AU - Larcombe-Young, Daniel
AU - Whilding, Lynsey
AU - Davies, David
AU - Draper, Benjamin
AU - Bechman, Natasha
AU - Maher, John
N1 - Funding Information:
This work was supported by Leucid Bio , Cancer Research UK (CRUK) grant number A21623 , the British Lung Foundation ( MESOUK18-2 ), the Experimental Cancer Medicine Centre at King’s College London , the King’s Health Partners/King’s College London Cancer Research UK Cancer Centre, Kings Health Partners MRC Confidence in Concepts, and the National Institute for Health and Care Research ( NIHR ) Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London and/or the NIHR Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
Funding Information:
This work was supported by Leucid Bio, Cancer Research UK (CRUK) grant number A21623, the British Lung Foundation (MESOUK18-2), the Experimental Cancer Medicine Centre at King's College London, the King's Health Partners/King's College London Cancer Research UK Cancer Centre, Kings Health Partners MRC Confidence in Concepts, and the National Institute for Health and Care Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust and King's College London and/or the NIHR Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. L.W. B.D. and N.B. conducted experimental work. L.W. D.M.D. B.D. and J.M. designed and optimized the approach and interpreted the data. D.L.Y. and J.M. wrote the first draft of the manuscript. All authors reviewed and edited the manuscript. J.M. is scientific founder, chief scientific officer, and shareholder in Leucid Bio, which is a spin-out company focused on development of cellular therapeutic agents. D.L.Y. is undertaking a PhD studentship funded by Leucid Bio. B.D. has completed a PhD studentship funded by Leucid Bio. L.W. and D.M.D. were both formerly consultants to Leucid Bio. J.M. L.W. and B.D. are named inventors on a granted patent submitted in relation to this work while all authors are named inventors on submitted patents that relate to pCAR technology. D.M.D. and D.L.Y. are shareholders in Leucid Bio. B.D. is a shareholder in Autolus Therapeutics PLC.
Publisher Copyright:
© 2022
PY - 2022/6/17
Y1 - 2022/6/17
N2 - Dual co-stimulation may be harnessed using parallel chimeric antigen receptors(pCARs) in which two distinct co-stimulatory units are adjacently localized onthe plasma membrane. This protocol summarizes construct design, human Tcell isolation, retroviral transduction, tissue culture expansion, and preclinicaltesting of pCAR T cells, exemplified by receptors that co-target avb6 integrinand ErbB dimers.For complete details on the use and execution of this protocol, please refer toMuliaditan et al. (2021).
AB - Dual co-stimulation may be harnessed using parallel chimeric antigen receptors(pCARs) in which two distinct co-stimulatory units are adjacently localized onthe plasma membrane. This protocol summarizes construct design, human Tcell isolation, retroviral transduction, tissue culture expansion, and preclinicaltesting of pCAR T cells, exemplified by receptors that co-target avb6 integrinand ErbB dimers.For complete details on the use and execution of this protocol, please refer toMuliaditan et al. (2021).
UR - http://www.scopus.com/inward/record.url?scp=85130938586&partnerID=8YFLogxK
U2 - 10.1016/j.xpro.2022.101414
DO - 10.1016/j.xpro.2022.101414
M3 - Article
VL - 3
JO - STAR Protocols
JF - STAR Protocols
IS - 2
M1 - 101414
ER -
